Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States
Top Cited Papers
Open Access
- 1 March 2011
- journal article
- research article
- Published by American Society for Microbiology in mBio
- Vol. 2 (1), e00309-10-10
- https://doi.org/10.1128/mbio.00309-10
Abstract
A seven-valent pneumococcal conjugate vaccine (PCV7) introduced in the United States in 2000 has been shown to reduce invasive pneumococcal disease (IPD) in both vaccinated children and adults through induction of herd immunity. We assessed the impact of infant immunization on pneumococcal pneumonia hospitalizations and mortality in all age groups using Health Care Utilization Project State Inpatient Databases (SID) for 1996 to 2006 from 10 states; SID contain 100% samples of ICD9-coded hospitalization data for the selected states. Compared to a 1996–1997 through 1998–1999 baseline, by the 2005–2006 season, both IPD and pneumococcal pneumonia hospitalizations and deaths had decreased substantially in all age groups, including a 47% (95% confidence interval [CI], 38 to 54%) reduction in nonbacteremic pneumococcal pneumonia (ICD9 code 481 with no codes indicating IPD) in infants IMPORTANCE Pneumonia is the world’s leading cause of death in children and the leading infectious cause of death among U.S. adults 65 years old and older. Pneumococcal conjugate vaccination of infants has previously been shown to reduce invasive pneumococcal disease (IPD) among seniors through prevention of pneumococcal transmission from infants to adults (herd immunity). Our analysis documents a significant vaccine-associated reduction not only in IPD but also in pneumococcal pneumonia hospitalizations and inpatient mortality rates among both vaccinated children and unvaccinated adults. We estimate that fully 90% of the reduction in the pneumonia hospitalization burden occurred among adults. Moreover, states that more rapidly introduced their infant pneumococcal immunization programs had greater reductions in influenza-associated pneumonia hospitalization of children, presumably because the vaccine acts to prevent the pneumococcal pneumonia that frequently follows influenza virus infection. Our results indicate that seven-valent pneumococcal conjugate vaccine use has yielded far greater benefits through herd immunity than have previously been recognized.Keywords
This publication has 38 references indexed in Scilit:
- Available evidence points to low effectiveness of influenza vaccines for older peopleBMJ Evidence-Based Medicine, 2010
- Global, regional, and national causes of child mortality in 2008: a systematic analysisThe Lancet, 2010
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Influenza Vaccination and Mortality: Differentiating Vaccine Effects From BiasAmerican Journal of Epidemiology, 2009
- Pneumonia After Implementation of the Pneumococcal Conjugate Vaccine Program in the Province of Quebec, CanadaThe Pediatric Infectious Disease Journal, 2008
- Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control studyThe Lancet, 2008
- Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialThe Lancet, 2005
- Epidemiological differences among pneumococcal serotypesThe Lancet Infectious Diseases, 2005
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionThe New England Journal of Medicine, 2003